EMD Millipore: Reput(Ab)le – Cancer-Signaling Antibodies
With EMD Millipore’s comprehensive portfolio of reagents and antibodies, researchers can count on dependable, high-quality solutions for analysing all the hallmarks of cancer…
Recognising both the tremendous opportunities and the challenges facing cancer researchers, EMD Millipore is dedicated to developing and refining tools and technologies for the study of cancer. With EMD Millipore’s comprehensive portfolio of reagents and antibodies, researchers can count on dependable, high-quality solutions for analysing all the hallmarks of cancer.
Downloads
Feature: Reput(Ab)le – Cancer-Signaling Antibodies
Related content from this organisation
- Biotech leader champions targeted cancer treatments and diversity
- Product hub: Light the path to your next neuroscience discovery with a new ultrasensitive NF-L immunoassay
- A high-throughput macrodomain assay to identify coronavirus drugs
- Building a powerful portfolio of sepsis biomarker signatures for therapeutic clinical trials
- Drug Target Review Assays ebook 2022
Related topics
Assays, Drug Discovery Processes, Drug Targets, Screening, Stem Cells, Translational Science
Related organisations
Merck KGaA